Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Mar;20(3):425-434.
doi: 10.1080/14787210.2021.1982695. Epub 2021 Sep 29.

Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis

Ronal Yosua Limen  1 , Rudyanto Sedono  1 , Adhrie Sugiarto  1 , Timotius Ivan Hariyanto  1   2
Affiliations
Meta-Analysis

Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis

Ronal Yosua Limen et al. Expert Rev Anti Infect Ther. 2022 Mar.

Abstract

Background: Currently, JAK-inhibitors are repurposed for therapy of Covid-19 because of their ability in restraining immune response, yet the corroboration regarding their advantage is still unclear. This study sought to analyze the efficacy of JAK-inhibitors to ameliorate the outcomes of Covid-19 sufferer.Research design and methods: Using specific keywords, we comprehensively go through the potential articles on ClinicalTrials.gov, Europe PMC, and PubMed sources until June 2nd, 2021. All published studies on JAK-inhibitors and Covid-19 were collected.

Results: There were 14 studies with 4,363 Covid-19 patients contained in the meta-analysis. Based on our data, we suggested that JAK-inhibitors corresponded with increased recovery rate (RR 1.17; 95%CI: 1.01-1.36, p= 0.040, I2 = 91%, random-effect modeling); shortened time to recovery (mean difference -0.96; 95%CI: -1.15, -0.77, p< 0.00001, I2 = 28%, random-effect modeling); reduction of clinical deterioration risk (RR 0.66; 95%CI: 0.48-0.89, p= 0.008, I2 = 57%, random-effect modeling); and reduction of Covid-19 mortality (RR 0.52; 95%CI: 0.36-0.76, p= 0.0006, I2 = 33%, random-effect modeling).

Conclusions: This study propose that JAK-inhibitors perhaps provide advantageous effects on Covid-19 outcomes. JAK-inhibitors may be given during 1-2 weeks of disease to optimize its beneficial effects in halting the exaggerated immune response.

Keywords: Coronavirus disease 2019; Covid-19; JAK-inhibitors; baricitinib; treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PRISMA diagram of the detailed process of selection of studies for inclusion in the systematic review and meta-analysis
Figure 2.
Figure 2.
Forest plot that demonstrates the association of JAK-inhibitors administration with recovery rate (a), time to recovery (b), clinical deterioration (c), and mortality (d) outcomes
Figure 3.
Figure 3.
Funnel plot analysis for the association of JAK-inhibitors administration with recovery rate (a), time to recovery (b), clinical deterioration (c), and mortality (d) outcomes
See this image and copyright information in PMC

References

    1. World Health Organization . Coronavirus disease (COVID-19): situation report. Accessed 2021 Jun 6. https://www.who.int/publications/m/item/weekly-epidemiological-update-on...
    1. Hariyanto TI, Rizki NA, Kurniawan A.. Anosmia/hyposmia is a good predictor of coronavirus disease 2019 (COVID-19) infection: a meta-analysis. Int Arch Otorhinolaryngol. 2020. DOI:10.1055/s-0040-1719120 - DOI - PMC - PubMed
    1. Kwenandar F, Japar KV, Damay V, et al. Coronavirus disease 2019 and cardiovascular system: a narrative review. Int J Cardiol Heart Vasc. 2020;29:100557. - PMC - PubMed
    1. Putri C, Hariyanto TI, Hananto JE, et al. Parkinson’s disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: a systematic review, meta-analysis, and meta-regression. Parkinsonism Relat Disord. 2021. Apr 24;S1353-8020(21)00152–8. DOI:10.1016/j.parkreldis.2021.04.019. - DOI - PMC - PubMed
    1. Hariyanto TI, Rosalind J, Christian K, et al. Human immunodeficiency virus and mortality from coronavirus disease 2019: a systematic review and meta-analysis. South Afr J HIV Med. 2021. Apr 15;22(1):1220. - PMC - PubMed

LinkOut - more resources